SCHEMBL2265108

SCHEMBL2265108

N#Cc1c(C(F)(F)F)cc(-c2ccccc2)n(Cc2ccc(Cl)cc2)c1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.65
HPGD P15428 5/20 0.65
ALDH1A1 P00352 10/20 0.59
PPARG P37231 1/20 0.59
NCOA2 Q15596 1/20 0.59
NCOA1 Q15788 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
NCOA3 Q9Y6Q9 1/20 0.59
RXRA P19793 3/20 0.55
NR1H2 P55055 3/20 0.55
NR1H3 Q13133 3/20 0.55
POLB P06746 2/20 0.51
MAPT P10636 3/20 0.47
CNR1 P21554 2/20 0.47
GLA P06280 3/20 0.46
GAA P10253 3/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2262871 0.93 RXRA (0.59) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2262221 0.93 RXRA (0.59) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2263112 0.91 RXRA (0.55) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2265348 0.91 RXRA (0.63) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2261582 0.90 KDM4E (0.53) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL14944114 0.90 RXRA (0.54) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2265833 0.90 KDM4E (0.55) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2262278 0.90 RXRA (0.54) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2262929 0.89 KDM4E (0.55) KDM4EHPGDALDH1A1PPARGNCOA2
SCHEMBL2263687 0.89 RXRA (0.58) KDM4EHPGDALDH1A1PPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465869-B1 MODULATORS OF LXR EXELIXIS PATENT CO LLC (US) 2013-05-15 EP disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 KDM4E 1528/4885HPGD 374/4885ALDH1A1 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.